Prostatype Genomics AB announces outcome of rights issue of units
The subscription period in Prostatype Genomics AB’s (”Prostatype Genomics” or the “Company”) rights issue, in which the public was also given the opportunity to participate, ended on 20 July 2022. The rights issue was subscribed (including pre-subscription commitments) to a total of approximately 79.5 percent, meaning that a guarantee commitment of approximately 20.5 percent has been activated to reach a total subscription of 100 percent. Prostatype Genomics will thus be provided proceeds of approximately SEK 22.5 million before deduction of transaction related costs. Settlement notes are